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Background: GLP-1 is an incretine hormone which gets secreted from intestinal L-cells in response to nutritional
stimuli leading to pancreatic insulin secretion and suppression of glucagon release. GLP-1 further inhibits gastric
motility and reduces appetite which in conjunction improves postprandial glucose metabolism. Additional
vasoprotective effects have been described for GLP-1 in experimental models. Despite these vasoprotective actions,
associations between endogenous levels of GLP-1 and cardiovascular disease have yet not been investigated in
humans which was the aim of the present study.
Methods: GLP-1 serum levels were assessed in a cohort of 303 patients receiving coronary CT-angiography due to
typical or atypical chest pain.
Results: GLP-1 was found to be positively associated with total coronary plaque burden in a fully adjusted model
containing age, sex, BMI, hypertension, diabetes mellitus, smoking, triglycerides, LDL-C (low density lipoprotein
cholesterol), hsCRP (high-sensitive C-reactive protein), and eGFR (estimated glomerular filtration rate)
(OR: 2.53 (95% CI: 1.12 – 6.08; p = 0.03).
Conclusion: Circulating GLP-1 was found to be positivity associated with coronary atherosclerosis in humans. The
clinical relevance of this observation needs further investigations.
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Hyperglycemia and insulin resistance are determinants
of cardiovascular risk with fasting blood glucose and in-
sulin concentrations being directly predictive for future
cardiovascular events [1,2]. Nevertheless, intensified glu-
cose lowering therapies have failed to substantially lower
cardiovascular risk in diabetic patients [3].
Recent reports suggest GLP-1 modulating drugs to hold
beneficial cardiovascular characteristics [4]. GLP-1 is an
incretine hormone which is secreted from intestinal L-cells
in response to nutritional stimuli. Circulating GLP-1 binds
to its receptor expressed on pancreatic beta-cells leading to
glucose dependent insulin secretion. In addition, GLP-1
suppresses glucagon release from pancreatic alpha cells,* Correspondence: mlehrke@ukaachen.de
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distribution, and reproduction in any mediumimpairs gastric motility and reduces appetite which in con-
junction improves postprandial glucose metabolism [5].
Furthermore, anti-inflammatory and atheroprotective ef-
fects have been described for GLP-1 which extends to
cardioprotection during acute myocardial infarction [4].
Relevance of endogenous GLP-1 serum levels for cardio-
vascular risk prediction in humans has so far not been con-
sidered. Impaired GLP-1 secretion has been reported in
obese and diabetic subjects in some studies [6-8]. This was
however not confirmed in a recent meta-analysis which
reported increased GLP-1 serum concentrations in diabetic
individuals [9]. Similarly, others have found elevated GLP-
1 serum levels in obesity and insulin resistance [10]. This
study aimed to assess associations between GLP-1 serum
levels and coronary atherosclerosis in humans.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Values are presented as n or median
(interquartile range)
Characteristics n = 303
Age (yrs) 63 (55–70)
Sex
Male 202
Female 101
Body mass index (kg/m2) 26.2 (24.1-29.0)
Hypertension*
Yes 147
No 126
Diabetes mellitus*
Yes 20
No 253
Smoker†
Yes 42
No 230
Family history of CAD†
Yes 77
No 195
Laboratory profile
LDL-cholesterol (mg/dl) 122 (95–149)
HDL-cholesterol (mg/dl) 52 (44–59)
Triglycerides (mg/dl) 143 (106–207)
High-sensitivity CRP (mg/dl) 0.23 (0.05-0.54)
TNFa (pg/ml) 6,3 (4.5-7.9)
eGFR (ml/min) 71 (63–80)
IL6 (pg/ml) 0 (0–3.2)
GLP-1 (pM) 2.9 (1.5-4.9)
Medical treatment‡
Statin 120
Aspirin, Plavix or Marcumar 170
Betablocker 173
ACE-I or ARB 138
Diuretics 87
Insulin or OAD 16
CT data
Pericardial adipose tissue volume (ml)§ 190 (132–259)
Number of coronary artery plaques (total)|| 3 (1–6) (range 0–26)
Number of calcified plaques 1 (0–3) (range 0–22)
Number of mixed plaques 0 (0–1) (range 0–10)
*History of diabetes and hypertension is known in 273 patients.
†History of smoking and family history of CAD is known in 272 patients.
‡Medication is known in 258 patients.
§Adequate image quality for evaluation of PAT volume was obtained in
287 patients.
||Adequate image quality for evaluation of coronary plaques was obtained in
281 patients.
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Blood samples were collected randomly (independent of
fasting) in 303 consecutive patients who underwent DSCT-
coronary angiography for exclusion of coronary artery
stenosis due to stable typical or atypical chest pain. De-
tailed information regarding recruitment, baseline charac-
teristics, dual-source multi-slice CT-coronary angiography,
dual-source CT image analysis, pericardial fat assessment,
and laboratory procedures have previously been published
and are summarized in Table 1. Briefly, the coronary tree
was segmented according to the suggestions of the AHA
into a 15 segment model. Each segment was further di-
vided into a proximal and a distal segment. Each segment
was then classified as containing or not containing a
plaque. Based on the number of diseased segments a
plaque score was calculated. Adequate image quality for
evaluation of coronary plaques was obtained in 281 of 303
patients. The study protocol was approved by the Ethics
Committee of the Ludwig-Maximilians-University Munich.
Protein chemistry
GLP-1 serum levels were determined using chemilumin-
escent enzyme-linked immunosorbent assay (ELISA)
after ethanol extraction from 300 ul of plasma.
Antibodies were purchased from Bioporto (Gentofte,
Denmark). The primary antibody was HYB 147–06,
which reacts with the amidated C-terminus of GLP-1
(1-36amide), GLP-1 (7-36amide) and GLP-1 (9-36amide).
The detection antibody was biotinylated HYB 147–12
which reacts to the mid-molecular epitope of GLP-1. The
Intra-Assay and Inter-Assay CV were 7.29% and 12.79%.
The assay did provide a linear standard curve (R = 0.98)
with the lowest standard being used at 1.5 pM which
provided a 10 fold higher signal than the blank sample.
Samples were stored at −70˚ with one freeze/thaw cycle
performed before GLP-1 measurement. We have found
excellent freeze/thaw stability of GLP-1 in human plasma
samples. Detection of GLP-1 after 1 to 4 freeze/thaw cy-
cles in probes from 3 different individuals yielded an
intra-assay variability of 9,23% which is comparable to the
general intra-assay variability. To further validate the assay
we performed mixing and spiking experiments. The mix-
ture of equal amounts of two different plasma samples
performed for 3 different pairs of samples provided a
mean recovery of 93% of the expected GLP-1 concentra-
tion. Spiking experiments of 5, 10, 50, 100 and 500 pM
standards to a known plasma sample provided a mean re-
covery of 91% of the expected concentration.
Statistics
A multiple logistic regression model based on complete
cases was used where the effect of GLP1 is adjusted for
age, sex, BMI, hypertension, diabetes, smoking, LDL, CRP,
GFR and triglycerides. Fractional polynomials were used
Table 2 Multivariate Association of GLP-1 and relevant
cardiovascular risk factors with total plaque burden as
assessed by CT-angiography
Variables Total plaque
OR (CI) p
log GLP-1 2.53 (1.12 – 6.08) 0.03
Age 1.15 (1.10 – 1.22) < 0.001
Sex 13.92 (4.47 – 51.53) < 0.001
BMI 1.20 (1.05 – 1.39) 0.01
Hypertension 1.01 (0.38 – 2.65) 0.98
Diabetes 2.11 (0.47 – 12.42) 0.36
Smoking 6.04 (1.37 – 35.42) 0.03
LDL 1.00 (0.99 – 1.01) 0.80
log CRP 1.15 (0.45 – 3.18) 0.78
log TG 2.22 (0.71 – 7.41) 0.18
log eGFR 1.15 (0.08 – 18.37) 0.92
Odds ratio and 95% CI increase in plaque quantity for 1 pM of total GLP-1
raise in plasma levels are presented.
Abbreviations: LDL (low density cholesterol), CRP (hsCRP), TG (triglyceride), eGFR
(estimate glomerular filtration rate), log. Logarithmic.
Bold numbers indicate significant associations with p < 0.05.
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covariates and the logarithmic odds for plaques. Further,
generalized variance inflation (gVIF) factors were used for
evaluating the presence of multicollinearity. A gVIF greater
than 4.0 is usually indicates substantial multicollinearity.
As a result of the multiple logistic regression model, odds
ratios with corresponding 95% confidence intervals and p-
values (two-sided) are reported. A p-value of lower than
0.05 is considered statistically significant. To evaluate the
relationship between GLP1 and triglyceride and between
GLP1 and eGFR, linear regressions based on complete
cases with each variable transformed by the natural loga-
rithm were used and the regression coefficients are
reported. All statistical analyses were performed by using
the statistical software R (version 2.13.1).
Results
Levels of total GLP-1 are associated with coronary plaque
burden in humans
Serum concentrations of GLP-1 were assessed in a cohort
of 303 patients undergoing coronary artery CT angiog-
raphy due to typical or atypical chest pain. Baseline char-
acteristics of the study have been published previously and
are presented in Table 1 [11]. Briefly, the mean age of the
study population was 63 years, 33% were female, the body
mass index was 26.2 kg/m2, hypertension was present in
48%, family history of coronary artery disease (CAD) in
25%, 7.2% were smokers and 7% had diabetes. The mean
amount of coronary plaque burden detected by CT angi-
ography was 3 (range 0 to 26) with no coronary plaques
being detectable in 60 patients. Median GLP-1 in random
non-fasting serum samples was 2.9 pM (IQR: 1.5-4.9).
Using spearman association GLP-1 (log scale) was found
to positively correlate with serum triglycerides (log scale)
(Rho: 0.27; p < 0.0001), while a weak negative correlation
was found with kidney function as defined by eGFR
(estimate glomerular filtration rate; log scale) (RHO: -0.14;
p < 0.05). Additional regression beta analysis for these two
parameters found a statistically significant relationship
between GLP-1 and triglycerides (regression coefficient:
0.35 (95% confidence interval: 0.18-0.52)) and a near-
significant relationship between GLP1 and eGFR (re-
gression coefficient: -0.38 (95% confidence interval:
-0.77-0.01)). No obvious correlation was detected with
other cardiovascular risk factors in the total cohort.
Within the framework of the multiple logistic regression
model, non-linear relationships were detected for GLP1,
CRP, triglyceride and GFR. For these four variables each
non-linearity is best modeled by taking the natural loga-
rithm of GLP1, CRP, triglycerides and eGFR. Besides, the
maximum of the observed generalized variance inflation
factors was 2.08 for age which indicates the absence of ser-
ious multicollinearity problems. The multiple logistic re-
gression model revealed that the logarithm of GLP-1 wassignificantly associated with total coronary plaque burden
in a model adjusted for age, sex, BMI, hypertension, dia-
betes, smoking, LDL, log. CRP, log. eGFR and log. triglyc-
erides (OR: 2.53; 95% CI: 1.12-6.08; p = 0.03) (Table 2).
The unadjusted OR for GLP-1 with total coronary plaque
burden was 2.12 (95% CI: 1.15-4.08; p = 0.02).
Discussion
In this study we found a positive association between
GLP-1 serum levels and coronary artery disease in
humans. This observation seems surprising taking the
vasoprotective efficacy described for GLP-1 and its ana-
logues in experimental models which seem to be con-
firmed by early clinical observations [4,12]. Furthermore,
inhibition of DPP-4 dependent degradation of GLP-1
was found to reduce atherogenesis and increase plaque
stability in mice while preliminary clinical data suggest
similar vasoprotective efficacy in humans [13,14]. Never-
theless, others have reported GLP-1 serum levels to be
increased in patients with high cardiovascular risk due
to accumulation of components of the metabolic syn-
drome and type 2 diabetic subjects [9,10]. Our study
confirms the previously described positive association
between GLP-1 serum levels and serum triglycerides
[10]. Increased GLP-1 concentrations in states of meta-
bolic risk like hypertriglyceridemia could represent a
counter regulation to increase insulin secretion in states
of insulin resistance. Consistently, GLP-1 serum concen-
trations were recently found to be increased in type 2
diabetic patients [9]. Still long term treatment with GLP-
1 analogues significantly improved glycemic control and
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cular risk factor in type 2 diabetic patients [15,16]. In
addition, GLP-1 analogues were found to be non-
inferior to metformin treatment in respect to circulating
markers of inflammation, oxidative stress and vascular
function in a 3 month lasting clinical trail [17] while
protective effects of GLP-1 analogues were found in he-
patocytes under ischemic stress [18].
GLP-1 is produced from intestinal L-cells from the
epithelial layer of the gut mucosa in response to food in-
gestion, parasympatic nervous activation and endocrine
mediators [5]. In addition IL6 as an inflammatory cyto-
kine was recently found to increase GLP-1 secretion
under in vitro and in vivo conditions [19]. Coronary ath-
erosclerosis is a chronic inflammatory disease process
which has been associated with IL6 [20]. We were how-
ever unable to detect associations between GLP-1 and
different mediators of inflammation including IL6 in our
population, making this an unlikely explanation.
Elimination of GLP-1 primarily depends on the kidney
with increased circulating concentrations of GLP-1 being
found in patients with chronic kidney disease and renal
failure [21,22]. Consistently we found weak negative as-
sociations of GLP-1 with kidney function in our popula-
tion. Chronic kidney disease is a major cardiovascular
risk factor. Nevertheless associations of GLP-1 and
atherosclerotic plaque burden remained significant after
adjustment for kidney function, making impaired GLP-1
elimination in states of renal disease an unlikely explan-
ation for the observed association of GLP-1 with coron-
ary artery disease.
Study limitations
Our study holds several strength and limitations. This is
the first study to establish a link between circulating serum
concentrations of GLP-1 and coronary artery disease. This
association remained significant in a fully adjusted model
after consideration of age, sex, BMI, hypertension, diabetes
mellitus, smoking, triglycerides, LDL-C, hsCRP, and eGFR.
However as this was an association study, this does not es-
tablish a causal relationship between GLP-1 and coronary
artery disease. Consequently, clinical implications of this
observation still need to be established. Experimental data
suggest vasoprotective efficacy of GLP-1, GLP-1 analoga
and DPP-4 inhibition [4] which are supported by prelimin-
ary clinical data [12,13]. The observed increase of GLP-1 in
context of vascular disease might therefore represent a
counter regulatory attempt to limit disease progression. In-
creased GLP-1 secretion in states of metabolic disease
might however also contribute to hyperinsulinemia which
has been linked with vascular disease [2].
The GLP-1 assay used in this study does detect active
GLP-1 in addition to processed metabolites of GLP-1.
These GLP-1 metabolites might hold own vascular actionswhich seem to be mediated independent of the GLP-1 re-
ceptor [23]. Additional studies are needed to further dis-
criminate associations between active GLP-1and its
metabolites with cardiovascular disease. Furthermore, sys-
temic and coronary artery concentrations of active GLP-1
might differ due to myocardial DPP-4 activity.
Serum samples in our study were collected randomly
independent of the last food intake. As food ingestion is
a strong stimulus of GLP-1 secretion this might have af-
fected the observed associations [6]. Additional studies
are needed to establish whether a similar link can be
found under fasting conditions. Non-fasting conditions
might however hold predictive relevance for some meta-
bolic biomarkers. This has earlier been reported for
serum triglycerides which better predicted cardiovascu-
lar risk when assessed in a non-fasting state [24].
Finally, our study results may only be applicable to non-
diabetic patients as diabetic patients were clearly under-
represented in the present study (7% of the patients).
Additional investigations in larger cohorts are needed
to further explore the association between GLP-1 and
cardiovascular disease in larger cohorts under consider-
ation of clinical outcome data.
In summary we found a surprising association of cir-
culating GLP-1 with coronary atherosclerosis in humans.
This might represent a contra-regulatory response in
states of increased metabolic risk which warrants further
investigations.
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